Terapia metronómica en el manejo del paciente veterinario con cáncer

María Lucía Suaréz, Rafaela Bortolotti Vièra, Annelise Carla Camplesi

Resumen


El cáncer es una problemática cada vez más frecuente en la práctica clínicade pequeños animales, para su control se emplean metodologías agresivascon múltiples efectos adversos, lo que ha estimulado la búsqueda denuevas estrategias terapéuticas. La quimioterapia metronómica consiste enla administración de bajas dosis de fármacos antineoplásicos, en intervalosregulares y por largos períodos de tiempo. Se destaca por su potencialantineoplásico, facilidad de administración y toxicidad reducida, mostrandobeneficio clínico en pacientes geriátricos, debilitados o con cáncer avanzado,logrado principalmente a través de la inhibición de la angiogénesis y lamodulación inmune antitumoral. En veterinaria, se relata principalmente eluso de ciclofosfamida, clorambucilo o lomustina, asociados en muchos casoscon otros fármacos, para el tratamiento de distintos tipos de tumores, con respuestas favorables y baja toxicidad. No obstante, los estudios existentes sonlimitados y en muchos casos la selección de la posología de administración de losfármacos ha sido empírica, perjudicando su eficacia terapéutica. El objetivo de esta revisiónes mostrar la utilidad de este tipo de quimioterapia antineoplásica en animalesdomésticos, los avances en la comprensión de sus mecanismos de acción, fármacos yesquemas utilizados, así como su potencial tóxico, buscando generar mayor concienciadel médico veterinario al utilizar esta modalidad de quimioterapia en pacientesoncológicos.

Abstract

Cancer is a frequent problem in veterinary practice in small animals; aggressive strategies with several side-effects are used to its control, which hasstimulated research of new therapeutic options. The metronomic chemotherapyconsists in regular administration of low doses of antineoplasticdrugs for long periods of time. Together with its antitumor potential, it isadministrated easily and has apparent reduced toxicity, showing clinicalbenefits within advanced diseases or geriatric and weak patients mainlyby angiogenesis inhibition and antitumor immune modulation. In smallanimals, cyclophosphamide, chlorambucil and lomustine have been usedmainly, in some cases associated with other drugs, to treat several kinds oftumors, obtaining clinical advantages and low toxicities. However, currentstudies are limited, and selection of most doses and intervals use to beempirical, in detriment of therapeutic efficacy. This work aims to evidencethe potential use of this kind of antineoplastic chemotherapy in domesticanimals, as well as the advances in comprehension of its mechanisms ofaction, drugs, schedules and toxic effects, trying to do a best and moreaware use of this chemotherapy strategy in oncologic patients.

Keywords: chemotherapy, dogs, low-dose, neoplasm, oncology.

Resumo

O câncer é um problema cada vez mais comum na rotina clínica de pequenos animais, epara seu controle são utilizadas metodologias agressivas com múltiplos efeitos adversos,o que estimula a busca de novas estratégias terapêuticas. A quimioterapia metronômicaconsiste na administração de baixas doses de drogas antineoplásicas, em intervalos regularese por longos períodos de tempo. Chama atenção devido ao por seu potencial antineoplásico,facilidade de administração e toxicidade reduzida, mostrando benefício clínicoem pacientes geriátricos, debilitados ou com câncer avançado, obtidos principalmente pormeio da inibição da angiogênese e da modulação imune antitumoral. Na medicina veterinária,o uso de ciclofosfamida, clorambucil ou lomustina, associado em muitos casos aoutras drogas, é relatado principalmente para o tratamento de diferentes tipos de tumores,com respostas favoráveis e baixa toxicidade. No entanto, os estudos existentes sãolimitados e, em muitos casos, a seleção da posologia da administração das drogas temsido empírica, prejudicando sua eficácia terapêutica. O objetivo desta revisão é mostrar autilidade deste tipo de quimioterapia antineoplásica em animais domésticos, os avançosna compreensão de seus mecanismos de ação, fármacos mais indicados e esquemas utilizados,bem como seu potencial tóxico, buscando gerar maior consciência do veterinárioao usar este tipo de quimioterapia em pacientes com câncer.

Palavras-chave: baixa dose, neoplasia, oncologia, cães, quimioterapia.

DOI: http://dx.doi.org/10.21615/cesmvz.12.3.3


Palabras clave


chemotherapy, dogs, low-dose, neoplasm, oncology.

Citas


Mutsaers AJ. Chemotherapy: new uses for old drugs. Vet Clin North Am Small Anim Pract 2007; 37(6): 1079–1090.

Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, et al. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol 2013; 6(5): 511–519.

Biller B. Metronomic chemotherapy in veterinary patients with cancer. Vet Clin North Am Small Anim Pract 2014; 44(5): 817–829.

Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, et al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol 2015; 95(1): 46–61.

Burton JH, Mitchell L, Thamm DH, Dow SW, Biller BJ. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. J Vet Intern Med 2011; 25: 920 – 926.

Chen C, Doloff JC, Waxman DJ. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 2014; 16(1): 84–96.

Rajasekaran T, Ng Q, Tan DS, Lim W, Ang M, et al. Metronomic chemotherapy: A relook at its basis and rationale. Cancer Lett 2017; 388: 328–333.

Pang LY, Argyle DJ. Veterinary oncology: biology, big data and precision medicine. Vet J 2016; 213: 38–45.

WHO. Cancer. Media Centre 2017; [acceso: 3 de octubre de 2017]. URL: http://www.who.int/mediacentre/factsheets/fs297/en/.

Schleis, S. E. Cancer screening tests for small animals. Vet Clin NA Small Anim Pract 2014; 44:871–881.

Breen M. Update on Genomics in veterinary oncology. Top Companion Anim Med 2009; 24(3): 113–121.

Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000; 100: 57–70.

Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646–674.

Withrow SJ, Vale DM, Page R. Withrow and MacEwen’s Small Animal Clinical Oncology. 5ª ed. [S.l.]: Saunders Elsevier; 2012.

Takimoto CH. Maximum tolerated dose: clinical endpoint for a bygone era? Target Oncol 2009; 4(2): 143–147.

Hanahan D, Bergers G, Bergsland E. Less is, more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105(8): 1045–1047.

Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4(6): 423–436.

Loven D, Hasnis E, Bertolini F, Shaked Y. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov Today 2013; 18(3-4): 193–201.

Mutsaers AJ. Metronomic Chemotherapy. Top Companion Anim Med 2009; 24(3): 137–143.

Bouche G, André N, Banavali S, Berthold F, Berruti A, et al. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting. 24-25 June 2014, Milan. Ecancer Medical Science 2014; 8: 1–19.

Abu Lila AS, Ishida T. Metronomic chemotherapy and nanocarrier platforms. Cancer Lett 2017; 400: 232–242.

Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, et al. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Investig 2012; 92(7): 952–966.

Gaspar TB, Henriques J, Marconato L, Queiroga FL. The use of low-dose metronomic chemotherapy in dogs — insight into a modern cancer field. Vet Comp Oncol 2017; https://doi.org/10.1111/vco.12309.

Rodrigues DS, Mancera PFA, Pinho STR. Understanding the antiangiogenic effect of metronomic chemotherapy through a simple mathematical model. Physica A 2016; 464: 251–266.

Riesco-Martinez M, Parra K, Saluja R, Francia G, Emmenegger U. Resistance to metronomic chemotherapy and ways to overcome it. Cancer Lett 2017; 400: 311–318.

Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther 2008; 7(1): 79–89.

Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7(11): 834–846.

Hao Y, Yi S, Ruan J, Zhao L, Nan K. New insights into metronomic chemotherapy-induced immunoregulation. Cancer Lett 2014; 354: 220–226.

Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7(8): 455–465.

Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012; 23(8): 8–11.

Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, et al. Metronomic cyclophosphamide regimen selectively depletes CD4 +CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641–648.

Kerbel RS, Shaked Y. The potential clinical promise of ‘multimodality’ metronomic chemotherapy revealed by preclinical studies of metastatic disease. Cancer Lett 2017; 400: 293–304.

Felice F De, Benevento I, Musella A, Musio D, Tombolini V. Metronomic chemotherapy in head and neck cancer. Cancer Lett 2017; 400: 219–222.

Barbolosi D, Ciccolini J, Meille C, Elharrar X, Faivre C, et al. Metronomics chemotherapy: Time for computational decision support. Cancer Chemother. Pharmacol 2014; 74: 647–652.

Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol 2016; 13: 1–15.

Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, et al. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005; 14: 466–479.

Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer 2013; 49(16): 3387–3395.

Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005; 106(9): 3058–3061.

Pasquier E, Kieran MW, Sterba J, Shaked Y, Baruchel S, et al. Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Transl Oncol 2011; 4(4): 203–211.

Khadka A, Akhoon N. Metronomic chemotherapy: Low dose less toxic anticancer strategy. Int J Pharmacol Res 2016; 6: 195–199.

Shi H, Jiang J, Ji J, Shi M, Cai Q, et al. Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer. Cancer Lett 2014; 349(2): 128–135.

Penel N, Adenis A, Bocci G. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 2012; 82(1): 40–50.

Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22(3): 659–661.

Ledzewicz U, Schattler H. Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models? Cancer Lett 2017; 401: 74–80.

Chen Y, Chang M, Cheng W. Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Lett 2017; 400: 282–292.

Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13(1): 73–80.

Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006; 6: 225.

Khan OA, Blann AD, Payne MJ, Middleton MR, Protheroe AS, et al. Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer 2011; 104(12): 1822–1827.

Jung JY, Jang G, Song H, Kim HS, Choi DR, et al. Efficacy of metronomic chemotherapy with oral cyclophosphamide and methotrexate in patients with non-Hodgkin lymphoma: a retrospective analysis at a single institution. Int J Clin Exp Med 2016; 9(2): 3893–3900.

Ishida T, Shiraga E, Kiwada H. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model. J Control Release 134, 194–200.

Lana S, U’ren L, Plaza S, Elmslie R, Gustafson D, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 2007; 21: 764–769.

Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med 2008; 22(6): 1373–1379.

Marchetti V, Giorgi M, Fioravanti A, Finotello R, Citi S, et al. First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study. Invest New Drugs 2012; 30(4): 1725–1730.

Schrempp DR, Childress MO, Stewar JC, Tan KM, Gortari AE, et al. Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma. J Am Vet Med Assoc 2013; 242(11): 1534–1538.

Leo, C, Stell A, Borrego J, Martinez de Merlo E, Ruess-Melzer K, et al. Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia. J Feline Med Surg 2014; 16(8): 671–678.

Wendelburg KM, Price LL, Burgess KE, Lyons JA, Lew FH, et al. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001–2012). J Am Vet Med Assoc 2015; 247: 393–403.

Rasmussen RM, Kurzman ID, Biller BJ, Guth A, Vail DM. Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs. Vet Comp Oncol 2017; 15: 421–430.

Cancedda S, Marconato L, Meier V, Laganga P, Roos M, et al. Hypofractionated radiotherapy for macroscopic canine soft tissue sarcoma: A retrospective study of 50 cases treated with a 5 × 6 Gy protocol with or without metronomic chemotherapy. Vet Radiol Ultrasound 2016; 57(1): 75–83.

Montagna E, Cancello G, Dellapasqua S, Munzone E, Colleoni M. Metronomic therapy and breast cancer: a systematic review. Cancer Treat Rev 2014; 40(8): 942–950.

Livshits Z, Rao RB, Smith SW. An approach to chemotherapy – associated toxicity. Emerg Med Clin N Am 2014; 32(1): 167–203.

Emmenegger U, Man S, Shaked Y, Francia J, Wong JW, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004; 64(11): 3994–4000.

Jalali AS, Hasanzadeh S, Malekinejad H. Achillea millefolium inflorescence aqueous extract ameliorates cyclophosphamide-induced toxicity in rat testis: stereological evidences. Chin J Nat Med 2012; 10(4): 247–254.

Senthilkumar S, Devaki T, Manohar BM, Babu MS. Effect of squalene on cyclophosphamide-induced toxicity. Clin Chim Acta 2005; 364(1-2): 335–342.

Viéra RB, Correal ML, Sierra OS, Martinato F, Santos MQP, et al. Cistite hemorrágica estéril por uso de ciclofosfamida em cão: relato de caso. J Bras Ciência An (Anais do Onco in Rio) 2016; S: 7–10.

Masci G, Losurdo A, Gandini C, Garassino I, Di Tomasso L, et al. Low-dose ‘metronomic chemotherapy’ with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit. Ecancer Medical Science 2012; 6(1): 1–5.

Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, et al. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev 2014; 13: 1109–1113.

André N, Abed S, Orbach D, Alla CA, Padovani L, et al. Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget 2011; 2(12): 960–965.

Maggo G, Grover SC, Grin A. Capecitabine induced colitis. Pathol - Res Pract 2014; 210(9): 606–608.

Tripp CD, Fidel J, Anderson CL, Patrick M, Pratt C, et al. Tolerability of metronomic administration of lomustine in dogs with cancer. J Vet Intern Med 2011; 25(2):

–284.

Saba, Khan S, Parvez S, Chaudhari B, Ahmad F, et al. Ellagic acid attenuates bleomycin and cyclophosphamide-induced pulmonary toxicity in Wistar rats. Food Chem Toxicol 2013; 58: 210–219.

Mitchell L, Thamm DH, Biller BJ. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med 2012; 26(2): 355–362.


Texto completo: PDF

Licencia de Creative Commons

Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.